Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma - Trial NCT05733715
Access comprehensive clinical trial information for NCT05733715 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abramson Cancer Center at Penn Medicine and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Abramson Cancer Center at Penn Medicine
Timeline & Enrollment
Phase 1
May 03, 2023
Jan 01, 2028
Primary Outcome
Change in frequency of progenitor exhausted CD8 T cells (TEX prog) in peripheral blood during neoadjuvant pembrolizumab +/- lenvatinib and in tumor tissue.
Summary
This study will evaluate the effect of investigational drugs, pembrolizumab alone or
 pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given
 before and after surgery to remove kidney cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05733715
Non-Device Trial